Pradaxa: licence extended for use in patients with atrial fibrillation

Pradaxa (dabigatran) is now licensed for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

Pradaxa is the first new treatment option for anticoagulation in atrial fibrillation | SCIENCE PHOTO LIBRARY
Pradaxa is the first new treatment option for anticoagulation in atrial fibrillation | SCIENCE PHOTO LIBRARY

Pradaxa (dabigatran) can now be considered for the prevention of stroke and systemic  embolism in at-risk patients with atrial fibrillation (AF), as an alternative to warfarin. Unlike warfarin, no loading dose is required with dabigatran, nor regular blood tests to monitor INR.  However, the monitoring of dabigatran-related anticoagulation may be helpful to prevent dabigatran overexposure in the presence of additional risk factors eg, ≥75 years, renal impairment or low body weight.

In the non-inferiority RE-LY study, 18113 patients with AF and risk factors for stroke were randomised and allocated to receive either dabigatran, blinded and using fixed doses of 110mg or 150mg twice daily, or open-label warfarin, adjusted according to INR. Rate of stroke or systemic embolism was used as the primary efficacy measure. Additionally, the rate of major bleed was identified as a measure of safety and defined as a ≥20g/litre reduction in haemoglobin level, transfusion of ≥2 units of blood, or symptomatic bleeding in a critical area or organ. The median duration of follow up was 2.0 years.

Results found dabigatran to be non-inferior to warfarin in reducing the rate of stroke or systemic embolism at the lower dose and displayed superior efficacy at the higher dose (rate per year: warfarin 1.71%; low dose dabigatran 1.54%; high dose dabigatran 1.11% [95% CI; p<0.001 for non-inferiority and superiority, respectively]).

The rates of major bleed were comparable between the warfarin and high dose dabigatran groups (relative risk 0.93 [95% CI; p<0.32]) but significantly lower when comparing the warfarin and low dose dabigatran group (relative risk 0.80 [95% CI; p<0.003]).

Only Pradaxa 110mg and 150mg capsules are licensed for this new indication.

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

NICE recommends dabigatran as an option in thromboembolism

NICE recommends dabigatran as an option in thromboembolism

NICE has recommended that dabigatran etexilate (Pradaxa)...

Pradaxa now indicated for DVT and PE

Pradaxa now indicated for DVT and PE

Pradaxa (dabigatran) is now licensed for the treatment...

Pradaxa: safety update owing to risk of serious haemorrhage

Pradaxa: safety update owing to risk of serious haemorrhage

The MHRA has issued updated safety advice for the anticoagulant...

Exembol: anticoagulant licensed in heparin-induced thrombocytopenia

Exembol: anticoagulant licensed in heparin-induced thrombocytopenia

Exembol (argatroban) is now available in the UK for...

NICE approves dabigatran in atrial fibrillation

NICE approves dabigatran in atrial fibrillation

Dabigatran etexilate (Pradaxa) can now be prescribed...

New oral anticoagulant approved

New oral anticoagulant approved

Apixaban is set to launch in the UK after being approved...

Apixaban 'better than aspirin' in atrial fibrillation

Apixaban 'better than aspirin' in atrial fibrillation

Researchers have stopped a Phase III trial of a new...



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more